Found: 5
Select item for more details and to access through your institution.
Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors.
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. e1189, doi. 10.1093/oncolo/oyae102
- By:
- Publication type:
- Article
First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. e1514, doi. 10.1002/onco.13817
- By:
- Publication type:
- Article
Significance of Mismatch Repair Protein Expression in the Chemotherapeutic Response of Sporadic Invasive Ductal Carcinoma of the Breast.
- Published in:
- Breast Journal, 2004, v. 10, n. 1, p. 20, doi. 10.1111/j.1524-4741.2004.09609.x
- By:
- Publication type:
- Article
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01095-1
- By:
- Publication type:
- Article
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1021, doi. 10.1007/s10637-022-01287-7
- By:
- Publication type:
- Article